

| OMB APPROVAL | |
|--|-----------|
| OMB Number: | 3235-0287 |
| Estimated average burden hours per response: | 0.5 |

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

| | | | | | | | | |
|---|---------|----------|--|--|--|--|--|--|
| 1. Name and Address of Reporting Person* <u>Hansard Adam</u> | | | 2. Issuer Name and Ticker or Trading Symbol <u>Applied Therapeutics Inc. [APLT]</u> | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Chief Commercial Officer</u> | | |
| (Last) | (First) | (Middle) | 3. Date of Earliest Transaction (Month/Day/Year) <u>08/02/2022</u> | | | 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person | | |
| C/O APPLIED THERAPEUTICS, INC. 545 FIFTH AVENUE, SUITE 1400 | | | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | |
| (Street) <u>NEW YORK NY 10017</u> | | | | | | | | |
| (City) (State) (Zip) | | | | | | | | |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | | | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|------------|-------|---|--|---|
| | | | Code | V | Amount | (A) or (D) | Price | | | |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
|--|--|--------------------------------------|--|--------------------------------|---|--|--------|--|-----------------|---|----------------------------|--|--|---|--|
| | | | | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | | |
| Employee Stock Option (Right to Buy) | \$2.02 | 08/02/2022 | | D ⁽¹⁾ | | | 50,000 | (2) | 04/13/2032 | Common Stock | 50,000 | (1) | 0 | D | |
| Employee Stock Option (Right to Buy) | \$1.05 | 08/02/2022 | | D ⁽¹⁾ | | 50,000 | | (2) | 04/13/2032 | Common Stock | 50,000 | (1) | 50,000 | D | |
| Employee Stock Option (Right to Buy) | \$4.17 | 08/02/2022 | | D ⁽¹⁾ | | 21,100 | | (3) | 01/07/2032 | Common Stock | 21,100 | (1) | 0 | D | |
| Employee Stock Option (Right to Buy) | \$1.05 | 08/02/2022 | | D ⁽¹⁾ | | 21,100 | | (3) | 01/07/2032 | Common Stock | 21,100 | (1) | 21,100 | D | |
| Employee Stock Option (Right to Buy) | \$9.44 | 08/02/2022 | | D ⁽¹⁾ | | 21,100 | | (4) | 12/14/2031 | Common Stock | 21,100 | (1) | 0 | D | |
| Employee Stock Option (Right to Buy) | \$1.05 | 08/02/2022 | | D ⁽¹⁾ | | 21,100 | | (4) | 12/14/2031 | Common Stock | 21,100 | (1) | 21,100 | D | |
| Employee Stock Option (Right to Buy) | \$23.15 | 08/02/2022 | | D ⁽¹⁾ | | 32,339 | | (5) | 12/10/2030 | Common Stock | 32,339 | (1) | 0 | D | |
| Employee Stock Option (Right to Buy) | \$1.05 | 08/02/2022 | | D ⁽¹⁾ | | 32,339 | | (5) | 12/10/2030 | Common Stock | 32,339 | (1) | 32,339 | D | |
| Employee Stock Option (Right to Buy) | \$34.28 | 08/02/2022 | | D ⁽¹⁾ | | 104,665 | | (6) | 03/09/2030 | Common Stock | 104,665 | (1) | 0 | D | |
| Employee Stock Option (Right to Buy) | \$1.05 | 08/02/2022 | | D ⁽¹⁾ | | 104,665 | | (6) | 03/09/2030 | Common Stock | 104,665 | (1) | 104,665 | D | |

Explanation of Responses:

- The transaction reported herein reflects a one-time stock option repricing that became effective on August 2, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options.
- Reflects an initial grant of 50,000 Options granted on April 13, 2022 that vests as follows: One-fourth (1/4th) of the shares subject to the compensatory Option shall vest on April 13, 2023, and one thirty-sixth (1/36th)

of the remaining shares subject to the compensatory Option shall vest each month thereafter, subject to the Reporting Person continuing to provide services through each such date.

3. Reflects an initial grant of 21,100 Options granted on January 7, 2022 that vests as follows: One-fourth (1/4th) of the shares subject to the compensatory Option shall vest on January 7, 2023, and one thirty-sixth (1/36th) of the remaining shares subject to the compensatory Option shall vest each month thereafter, subject to the Reporting Person continuing to provide services through each such date.

4. Reflects an initial grant of 21,100 Options granted on December 14, 2021 that vests as follows: One-fourth (1/4th) of the shares subject to the compensatory Option shall vest on December 14, 2022, and one thirty-sixth (1/36th) of the remaining shares subject to the compensatory Option shall vest each month thereafter, subject to the Reporting Person continuing to provide services through each such date.

5. Reflects an initial grant of 81,700 Options granted on March 9, 2020 that vests as follows: One-fourth (1/4th) of the shares subject to the Option shall vest on December 10, 2021, and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to provide services through each such date.

6. Reflects an initial grant of 179,425 Options granted on March 9, 2020 that vests as follows: One-fourth (1/4th) of the shares subject to the Option shall vest on March 9, 2021, and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to provide services through each such date.

Remarks:

/s/ Shoshana Shendelman, as
attorney-in-fact

08/04/2022

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.